Lung Cancer


 Stage IB, II, IIIA

  • Alliance A081105Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
  • Alliance A151216– Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
  • ECOG E4512– Randomized Phase III Double-Blind Trial for Surgical Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein


  • RTOG 0839 – Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) NSCLC
  • NRG LU001– A Randomized Phase II Trail of Concurrent Chemoradiotherapy +/- Metformin HL in Locally Advanced NSCLC
  • RTOG 1306– A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III NSCLC


  • SWOG S1400A Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Stage IIIB/IV  Lung Cancer (S1400E is permanently closed)
  • SWOG S1300– A Randomized Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK Positive Non-Squamous NSCLC Patients who have progressed systemically after previous clinical benefit from Crizotinib Monotherapy


  • ECOG E2511- Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Small Cell Lung Cancer
  • CALGB 30610– Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited SCLC also Receiving Cisplatin and Etoposide

Metastatic Lung Cancer

  •  RTOG 0631– A Randomized Phase II/III Study of Image Guided Radiosurgery/SBRT for Localized Spine Metastasis


  • SWOG S0905– Randomized Phase II Study of Cediranib (NSC #732208) Versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma